Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1

Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1

Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: European Journal of Cancer - Volume 90, February 2018, Pages 122-129

G.M. Haag, I. Zoernig, J.C. Hassel, N. Halama, J. Dick, N. Lang, L. Podola, J. Funk, C. Ziegelmeier, S. Juenger, M. Bucur, L. Umansky, C.S. Falk, A. Freitag, I. Karapanagiotou-Schenkel, P. Beckhove, A. Enk, D. Jaeger,